Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer And J&J Settle Remicade Antitrust Litigation

Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms

Executive Summary

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

You may also be interested in...



Pfizer Signals Waning Interest In Biosimilars

Despite commercial success in biosimilars, Pfizer said it is more interested in investing in innovative therapeutics.

Pfizer Asks For Biden’s Co-operation To Incentivize Biosimilar Uptake

Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled. 

Celltrion And Pfizer Cement Victory On Infliximab

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;